CDC’s Vaccines for Children Program Addendum : Special Considerations for Nirsevimab

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  Nirsevimab is an FDA-licensed monoclonal antibody that provides passive immunity against RSV-associated infection. On August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend nirsevimab as an immunization for all infants aged <8 months, as well as some children up to age 20 months (see ACIP recommendations), and a VFC resolution was passed to include nirsevimab in the VFC program. This addendum provides supplemental information and guidance related to the addition of the nirsevimab immunization to the VFC formulary. ; NCIRDwt ; operations-guide-nirsevimab-addendum.pdf
• Subjects:
  • Infant, Newborn
  • Pregnancy
  • Pregnant Women
  • Respiratory Syncytial Virus Infections/prevention & control
• Series:
  Vaccines for Children
• Document Type:
  Text
• Corporate as Subject:
  Nirsevimab ; Nirsevimab
• Genre:
  Fact Sheet
• Place as Subject:
  United States
• Pages in Document:
  2 unnumbered pages
• Download URL:
  https://stacks.cdc.gov/view/cdc/134195/cdc_134195_DS1.pdf
• File Type:
  [PDF - 156.47 KB]
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:4ff95ceb9233442704c70630b9e14fd8a616eb27d60d2afff87b1b88bac6c3d32ab11d5601f57d6956a435029f5a6c090a7700dc58f457846d3b34a5b838902c